Autopsy report · NCT04436120

Treatment Resistance Following Anti-cancer Therapies

“Study terminated due to lack of enrollment that has been compounded by the global COVID-19 pandemic. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months after it had already started.
• Ran for about 1 year 10 months before it stopped.
• 38 participants enrolled.
• Results were posted on the registry 4 years after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Pfizer

Sponsor type

Industry

Conditions

Disease Progression

Interventions

De novo tumor tissue biopsy; Research blood draws

Participants

38

Sites

33

Countries

Argentina, Belgium, France, United Kingdom, United States

Trials that died the same way

• An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
  “Study terminated due to lack of enrollment of the target population. There were no safety, efficacy, or regulatory interaction involved in the decision to stop enrollment.” (89% match in meaning)
• Changing Developmental Trajectories Through Early Treatment
  “Participant enrollment was hindered by the COVID-19 pandemic and the study was ultimately terminated.” (85% match in meaning)
• Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
  “The study was prematurely terminated by the Sponsor based on difficulties in meeting enrollment goals, especially during the COVID-19 pandemic, and not for reasons relating to any concerns regarding quality, safety, or efficacy.” (85% match in meaning)
• Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
  “The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.” (84% match in meaning)
• Anti-RSV Study in Chinese Patients (ASCENT)
  “The study was terminated early due to COVID-19-related enrollment disruptions, not as a result of any product safety concerns.” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.